These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33398196)

  • 1. Genetic screening for single-cell variability modulators driving therapy resistance.
    Torre EA; Arai E; Bayatpour S; Jiang CL; Beck LE; Emert BL; Shaffer SM; Mellis IA; Fane ME; Alicea GM; Budinich KA; Weeraratna AT; Shi J; Raj A
    Nat Genet; 2021 Jan; 53(1):76-85. PubMed ID: 33398196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.
    Salton M; Kasprzak WK; Voss T; Shapiro BA; Poulikakos PI; Misteli T
    Nat Commun; 2015 May; 6():7103. PubMed ID: 25971842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
    Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Codon-specific translation reprogramming promotes resistance to targeted therapy.
    Rapino F; Delaunay S; Rambow F; Zhou Z; Tharun L; De Tullio P; Sin O; Shostak K; Schmitz S; Piepers J; Ghesquière B; Karim L; Charloteaux B; Jamart D; Florin A; Lambert C; Rorive A; Jerusalem G; Leucci E; Dewaele M; Vooijs M; Leidel SA; Georges M; Voz M; Peers B; Büttner R; Marine JC; Chariot A; Close P
    Nature; 2018 Jun; 558(7711):605-609. PubMed ID: 29925953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.
    Kong X; Kuilman T; Shahrabi A; Boshuizen J; Kemper K; Song JY; Niessen HWM; Rozeman EA; Geukes Foppen MH; Blank CU; Peeper DS
    Nature; 2017 Oct; 550(7675):270-274. PubMed ID: 28976960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
    Emmons MF; Faião-Flores F; Sharma R; Thapa R; Messina JL; Becker JC; Schadendorf D; Seto E; Sondak VK; Koomen JM; Chen YA; Lau EK; Wan L; Licht JD; Smalley KSM
    Cancer Res; 2019 Jun; 79(11):2947-2961. PubMed ID: 30987999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.
    Rizzolio S; Cagnoni G; Battistini C; Bonelli S; Isella C; Van Ginderachter JA; Bernards R; Di Nicolantonio F; Giordano S; Tamagnone L
    J Clin Invest; 2018 Aug; 128(9):3976-3990. PubMed ID: 29953416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
    Phadke MS; Sini P; Smalley KS
    Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
    Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
    Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironment-derived factors driving metastatic plasticity in melanoma.
    Kim IS; Heilmann S; Kansler ER; Zhang Y; Zimmer M; Ratnakumar K; Bowman RL; Simon-Vermot T; Fennell M; Garippa R; Lu L; Lee W; Hollmann T; Xavier JB; White RM
    Nat Commun; 2017 Feb; 8():14343. PubMed ID: 28181494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
    Mazzio EA; Soliman KFA
    Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.
    Corre S; Tardif N; Mouchet N; Leclair HM; Boussemart L; Gautron A; Bachelot L; Perrot A; Soshilov A; Rogiers A; Rambow F; Dumontet E; Tarte K; Bessede A; Guillemin GJ; Marine JC; Denison MS; Gilot D; Galibert MD
    Nat Commun; 2018 Nov; 9(1):4775. PubMed ID: 30429474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.
    Li Z; Wang B; Gu S; Jiang P; Sahu A; Chen CH; Han T; Shi S; Wang X; Traugh N; Liu H; Liu Y; Wu Q; Brown M; Xiao T; Boland GM; Shirley Liu X
    Genomics Proteomics Bioinformatics; 2020 Feb; 18(1):26-40. PubMed ID: 32413516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
    Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
    Konermann S; Brigham MD; Trevino AE; Joung J; Abudayyeh OO; Barcena C; Hsu PD; Habib N; Gootenberg JS; Nishimasu H; Nureki O; Zhang F
    Nature; 2015 Jan; 517(7536):583-8. PubMed ID: 25494202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.